Erkang Pharmaceuticals: Net loss of 380 million yuan in 2025.

Er Kang Pharmaceutical announced that its operating income in 2025 was 1.166 billion yuan, a year-on-year increase of 2.29%. The net loss attributable to shareholders of the listed company was 380 million yuan, compared to a net loss of 373 million yuan in the same period of the previous year. The company plans not to distribute cash dividends, bonus shares, or increase capital reserves through bonus issues.